

REMARKS

Currently, claims 1-24 are pending in the present application. The Examiner has restricted the application as follows:

Groups 1-24, claims 1-3, 5-11,22, drawn to a chimeric protein comprising Chondroitinase Abc exolyase conjugated to neural cell adhesion molecule comprising N-VAM, LI-- -MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 1 refers to Chondroitinase Abc exolyase conjugated to N-VAM polypeptide, group 2 refers to Chondroitinase Abc exolyase conjugated to L1 molecules and so on.

Groups 25-48, claims 1-3, 5-11,22, drawn to a chimeric protein comprising Chondroitinase Abc endolyase conjugated to neural cell adhesion molecule comprising N-VAM, LI-- -MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 25 refers to

Chondroitinase Abc endolyase conjugated to N-VAM polypeptide, group 26 refers to Chondroitinase Abc endolyase conjugated to L1 and so on.

Groups 49-72, claims 1-3, 5-11,22, drawn to a chimeric protein comprising Chondroitinase AC conjugated to neural cell adhesion molecule comprising N-VAM, LI-- -MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 49 refers to Chondroitinase AC conjugated to N-VAM polypeptide, group 50 refers to Chondroitinase AC conjugated to L1 and so on.

Groups 73-96, claims 1-3, 5-11,22, drawn to a chimeric protein comprising Chondroitinase B conjugated to neural cell adhesion molecule comprising N-VAM, LI-- -MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 73 refers to Chondroitinase B conjugated to N-VAM polypeptide, group 74 refers to Chondroitinase C conjugated to L1 and so on.

Groups 97-120, claims 1-2, 4, 5-11, 22, drawn to a chimeric protein comprising MMP-9 conjugated to neural cell adhesion molecule comprising N-VAM, LI-- -MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 97 refers to MMP-9 conjugated to N-VAM polypeptide, group 98 refers to MMP-9 conjugated to L1 and so on.

Groups 121-144, claims 1-2, 4, 5-11, 22, drawn to a chimeric protein comprising MMP-2 conjugated to neural cell adhesion molecule comprising N-VAM, LI-- -MaG molecules or

neurotrophic factors (see 24 of them in claim 5) wherein group 121 refers to MMP-2 conjugated to N-VAM polypeptide, group 122 refers to MMP-2 conjugated to L1 and so on.

Groups 145-168, claims 1-2, 4, 5-11, 22, drawn to a chimeric protein comprising pepsin conjugated to neural cell adhesion molecule comprising N-VAM, L1-- --MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 145 refers to pepsin conjugated to N-VAM polypeptide, group 146 refers to pepsin conjugated to L1 and so on.

Groups 169-192, claims 12-21, 23-24, drawn to method of enhancing nervous system repair using chimeric protein comprising Chondroitinase ABC exolyase conjugated to neural cell adhesion molecule comprising N-VAM, L1-- --MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 169 refers to Chondroitinase ABC exolyase conjugated to N-VAM polypeptide, group 170 refers to Chondroitinase ABC exolyase conjugated to L1 molecules and so on.

Groups 193-216, claims 12-21, 23-24, drawn to method of enhancing nervous system repair using comprising chimeric protein comprising Chondroitinase ABC endolyase conjugated to neural cell adhesion molecule comprising N-VAM, L1-- --MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 193 refers to Chondroitinase ABC endolyase conjugated to N-VAM polypeptide, group 194 refers to Chondroitinase ABC endolyase conjugated to L1 and so on.

Groups 217-240, claims 12-21, 23-24, drawn to method of enhancing nervous system repair using comprising chimeric protein comprising Chondroitinase AC conjugated to neural cell adhesion molecule comprising N-VAM, LI-- -MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 217 refers to Chondroitinase AC conjugated to N-VAM polypeptide, group 218 refers to Chondroitinase AC conjugated to L1 and so on.

Groups 241-264, claims 12-21, 23-24, drawn to method of enhancing nervous system repair using comprising chimeric protein comprising Chondroitinase B conjugated to neural cell adhesion molecule comprising N-VAM, LI-- -MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 241 refers to Chondroitinase B conjugated to N-VAM polypeptide, group 242 refers to Chondroitinase C conjugated to L1 and so on..

Groups 265-288, claims 12-21, 23-24, drawn to method of enhancing nervous system repair using comprising chimeric protein comprising MMP-9 conjugated to neural cell adhesion molecule comprising N-VAM, LI-- -MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 265 refers to MMP-9 conjugated to N-VAM polypeptide, group 266 refers to MMP-9 conjugated to L1 and so on.

Groups 289-312, claims 12-21, 23-24, drawn to method of enhancing nervous system repair using comprising chimeric protein comprising MMP-2 conjugated to neural cell adhesion molecule comprising N-VAM, LI-- -MaG molecules or neurotrophic factors (see 24 of them

in claim 5) wherein group 289 refers to MMP-2 conjugated to N-VAM polypeptide, group 290 refers to MMP-2 conjugated to L1 and so on.

Groups 313-336, claims 12-21, 23-24, drawn to method of enhancing nervous system repair using comprising chimeric protein comprising pepsin conjugated to neural cell adhesion molecule comprising N-VAM, L1-- -MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 313 refers to pepsin conjugated to N-VAM polypeptide, group 336 refers to pepsin conjugated to L1 and so on.

Groups 337-360, claims 1-2, 4, 5-11, 22, drawn to a chimeric protein comprising hyaluronidases conjugated to neural cell adhesion molecule comprising N-VAM, L1-- -MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 337 refers to hyaluronidases conjugated to N-VAM polypeptide, group 338 refers to hyaluronidases conjugated to L1 molecules and so on.


Groups 361-384, claims 12-21, 23-24, drawn to a method of enhancing nervous system repair using comprising chimeric protein comprising hyaluronidases conjugated to neural cell adhesion molecule comprising N-VAM, L1-- -MaG molecules or neurotrophic factors (see 24 of them in claim 5) wherein group 361 refers to hyaluronidases conjugated to N-VAM polypeptide, group 362 refers to hyaluronidases conjugated to L1 molecules and so on.

Applicants elect without traverse Group 24 (Claims 1-3, 5-11, and 22) drawn to a chimeric protein comprising Chondroitinase ABC exolyase and neurotrophic factors. Applicants expressly reserve the right to present the claims of any of the unelected species or groups, in one or more continuation or divisional applications at a later date. Applicants note that one or more claims are generic and act as linking claims. Applicants expressly reserve the right of rejoinder for all of the claims upon allowance of any species or group.

CONCLUSION

It is not believed that any additional fee is required. However, the Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to deposit account no. 50-0436.

Respectfully submitted,



C. Allen Black, Jr.
Registration No. 53,835

PEPPER HAMILTON LLP
One Mellon Bank Center
50th Floor
500 Grant Street
Pittsburgh, PA 15219
Telephone: (412) 454-5004
Facsimile: (412) 281-0717
Date: August 28, 2008